Shen Hong C, Ding Fa-Xiang, Deng Qiaolin, Xu Suoyu, Tong Xinchun, Zhang Xiaoping, Chen Yuli, Zhou Gaochao, Pai Lee-Yuh, Alonso-Galicia Magdalena, Roy Sophie, Zhang Bei, Tata James R, Berger Joel P, Colletti Steven L
Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065-0900, USA.
Bioorg Med Chem Lett. 2009 Oct 1;19(19):5716-21. doi: 10.1016/j.bmcl.2009.08.006. Epub 2009 Aug 7.
Distinct from previously reported urea and amide inhibitors of soluble epoxide hydrolase (sEH), a novel class of inhibitors were rationally designed based on the X-ray structure of this enzyme and known amide inhibitors. The structure-activity relationship (SAR) study was focused on improving the sEH inhibitory activity. Aminobenzisoxazoles emerged to be the optimal series, of which a potent human sEH inhibitor 7t was identified with a good pharmacokinetics (PK) profile. The strategy of employing aminoheterocycles as amide replacements may represent a general approach to develop mimics of known hydrolase or protease inhibitors containing an amide moiety.
与先前报道的可溶性环氧化物水解酶(sEH)的尿素和酰胺抑制剂不同,基于该酶的X射线结构和已知的酰胺抑制剂,合理设计了一类新型抑制剂。构效关系(SAR)研究专注于提高sEH抑制活性。氨基苯异恶唑成为最佳系列,从中鉴定出一种具有良好药代动力学(PK)特征的强效人sEH抑制剂7t。采用氨基杂环作为酰胺替代物的策略可能代表了一种开发含酰胺部分的已知水解酶或蛋白酶抑制剂模拟物的通用方法。